S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:PSTXPoseida Therapeutics Stock Price, Forecast & News

$12.90
-0.18 (-1.38 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.76
Now: $12.90
$13.99
50-Day Range N/A
52-Week Range
$11.35
Now: $12.90
$17.62
Volume518,710 shs
Average Volume569,801 shs
Market Capitalization$797.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTX
CUSIPN/A
CIKN/A
Phone858-779-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees149
Market Cap$797.43 million
Next Earnings DateN/A
OptionableNot Optionable
$12.90
-0.18 (-1.38 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Poseida Therapeutics (NASDAQ:PSTX) Frequently Asked Questions

Has Poseida Therapeutics been receiving favorable news coverage?

Headlines about PSTX stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Poseida Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Poseida Therapeutics
.

Who are some of Poseida Therapeutics' key competitors?

Who are Poseida Therapeutics' key executives?

Poseida Therapeutics' management team includes the following people:
  • Dr. Eric M. Ostertag, CEO, Sec. & Director (Age 47, Pay $703.16k)
  • Mr. Kerry D. Ingalls, Chief Operating Officer (Age 58, Pay $384.98k)
  • Dr. Matthew A. Spear, Chief Medical Officer (Age 53, Pay $597.94k)
  • Mr. Mark J. Gergen, Pres, Chief Bus. Officer & Director (Age 57)
  • Ms. Johanna M. Mylet C.P.A., Sr. VP of Fin. (Age 33)

When did Poseida Therapeutics IPO?

(PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

What is Poseida Therapeutics' stock symbol?

Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."

When does Poseida Therapeutics' quiet period expire?

Poseida Therapeutics' quiet period expires on Wednesday, August 19th. Poseida Therapeutics had issued 14,000,000 shares in its initial public offering on July 10th. The total size of the offering was $224,000,000 based on an initial share price of $16.00. During Poseida Therapeutics' quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Poseida Therapeutics' stock price today?

One share of PSTX stock can currently be purchased for approximately $12.90.

How big of a company is Poseida Therapeutics?

Poseida Therapeutics has a market capitalization of $797.43 million. Poseida Therapeutics employs 149 workers across the globe.

What is Poseida Therapeutics' official website?

The official website for Poseida Therapeutics is www.poseida.com.

How can I contact Poseida Therapeutics?

Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-779-3100.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.